Second Generation" Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy

Inclusion Criteria:

• Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I,II, III, IV) OR unstable angina pectoris (Braunwald Classification B&C, I-II-III) OR patients with documented silent ischemia, all treated with a second generation drug eluting stent
• Presence of one or more de novo stenosis equal or greater than 70% in a native coronary artery, treated with a Resolute drug eluting stent
• Patient is > 18 years of age (or minimum age as required by local regulations).
• The patient has consented to participate by signing the "Patient Informed Consent Form""
• The patient is willing and able to cooperate with study procedures and required follow up visits
• Any type of lesion or number of lesion can be included in this trial unless specifically detailed in the exclusion criteria.
• At least one second generation DES implanted in the target lesion in the last 24 hours
• No other DES implanted before the target procedure
• No BMS implanted in the 12 months before the target procedure

Exclusion Criteria:

• Patients treated for lesions in venous or arterial grafts
• Patients treated for in-stent restenosis
• Patients treated for Unprotected Left Main lesions
• ST elevation myocardial infarction in the 48 hours prior to the procedure
• Non ST elevation myocardial infarction
• Patients with LVEF≤30%
• Women with known pregnancy or who are lactating
• Patients with hypersensitivity or allergies to hepari, or any other analogue or derivative, cobalt, chromium, nickel, molybdenum or contrast media.
• Patients with chronic renal insufficiency

• Contraindication to the use of clopidogrel and/or ASA:

  • History of drug allergy to thienopyridine derivatives or ASA
  • History of clinically significant or persistent thrombocytopenia or neutropenia
  • Active bleeding or significant risk of bleeding, such as elderly patients receining fibrinolytic therapy and other potent antithrombotic agents, severe hepatic insufficiency, current peptic ulceration, proliferative diabetic retinopathy
  • Uncontrolled hypertension
• Current medical condition with a life expectancy of less than 24 months.
• The subject is participating in another device or drug study
• Subject must have completed the follow-up phase of any previous study at least 30 days prior to enrolment in this trial.
• Patients with medical conditions that preclude the follow-up as defined in the protocol or that otherwise limits participation in this study